Phase 2 Start
IBRX: Phase 2 Start: Phase 1b/2, Open-Label Clinical Trial Evaluating the Safety and Efficacy of Nogapendekin Alfa Inbaki
September 15, 2026 · nogapendekin. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 15, 2026
- Company
- ImmunityBio, Inc. (IBRX)
- Drug
- nogapendekin
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: Phase 1b/2, Open-Label Clinical Trial Evaluating the Safety and Efficacy of Nogapendekin Alfa Inbaki
- Company
- ImmunityBio, Inc. (IBRX)
- Drug
- nogapendekin
- Indication
- Septic Shock; Sepsis